BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 29243413)

  • 1. Clinical response to apatinib monotherapy in advanced non-small cell lung cancer.
    Xu J; Liu X; Yang S; Zhang X; Shi Y
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):264-269. PubMed ID: 29243413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy.
    Liu Z; Ou W; Li N; Wang SY
    Thorac Cancer; 2018 Oct; 9(10):1285-1290. PubMed ID: 30126078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
    Wu D; Liang L; Nie L; Nie J; Dai L; Hu W; Zhang J; Chen X; Han J; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Xin T; Fang J
    Asia Pac J Clin Oncol; 2018 Dec; 14(6):446-452. PubMed ID: 29573236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non-small-cell Lung Cancer.
    Wu F; Zhang S; Xiong A; Gao G; Li W; Cai W; Su C; Chen X; Zhou F; Zhao J; Ren S; Zhou C
    Clin Lung Cancer; 2018 Nov; 19(6):e831-e842. PubMed ID: 30026059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment].
    Wang X; Zhang W; Du W; Zhang X; Ren X; Cao S
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):761-768. PubMed ID: 29167006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting.
    Leng J; Li DR; Huang LM; Ji XH; Wang DL
    Medicine (Baltimore); 2019 Sep; 98(36):e16967. PubMed ID: 31490378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.
    Zhang D; Zhang C; Huang J; Guan Y; Guo Q
    Thorac Cancer; 2018 Dec; 9(12):1754-1762. PubMed ID: 30338916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apatinib for advanced nonsmall-cell lung cancer: A retrospective case series analysis.
    Yang C; Feng W; Wu D
    J Cancer Res Ther; 2018 Jan; 14(1):159-162. PubMed ID: 29516980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases.
    Xu J; Liu X; Yang S; Shi Y
    Oncol Res; 2020 Mar; 28(2):127-133. PubMed ID: 31610827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
    Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
    Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
    Hu X; Zhang J; Xu B; Jiang Z; Ragaz J; Tong Z; Zhang Q; Wang X; Feng J; Pang D; Fan M; Li J; Wang B; Wang Z; Zhang Q; Sun S; Liao C
    Int J Cancer; 2014 Oct; 135(8):1961-9. PubMed ID: 24604288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma.
    Zeng DX; Lei W; Wang CG; Huang JA; Jiang JH
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):439-442. PubMed ID: 30547193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial.
    Zhang X; Xiong Y; Xia Q; Wu F; Liu L; Zhou Y; Zeng L; Zhou C; Xia C; Jiang W; Liao D; Xiao L; Liu L; Yang H; Guan R; Li K; Wang J; Lei G; Zhang Y; Yang N
    JAMA Netw Open; 2020 Mar; 3(3):e201226. PubMed ID: 32191330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of apatinib combined with chemotherapy for advanced non-small cell lung cancer with negative driving genes].
    Li YF; Jiang HY; Li Q; Zhu M; Lyu J; Zhao HY
    Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):775-781. PubMed ID: 31648501
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of apatinib monotherapy in elderly patients with advanced metastatic non-small cell lung cancer.
    Li J; Tong X; Li H
    Indian J Cancer; 2020; 57(1):13-17. PubMed ID: 32129295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous Low-Dose Apatinib Combined With WBRT Significantly Reduces Peritumoral Edema and Enhances the Efficacy of Symptomatic Multiple Brain Metastases in NSCLC.
    Ren Y; Wang SB; Zhou L; Liu SQ; Du LY; Li T; Jiang MQ; Lei KJ; Tan BX; Jia YM
    Technol Cancer Res Treat; 2021; 20():15330338211011968. PubMed ID: 33955301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study.
    Yan X; Wang Q; Wang H; Li P; Zhang G; Zhang M; Zheng X; Yang J; Zhang X; Ma Z
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):235-240. PubMed ID: 30293117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review.
    Wang Y; Li W; Jing N; Meng X; Zhou S; Zhu Y; Xu J; Tao R
    Cancer Biol Ther; 2020 Jul; 21(7):583-589. PubMed ID: 32212907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial.
    Yu Z; Cai X; Xu Z; He Z; Lai J; Wang W; Zhang J; Kong W; Huang X; Chen Y; Shi Y; Shi X; Zhao Z; Ni M; Lin X; Chen S; Wu X; Chen W; Song Z; Huang C
    Oncologist; 2020 Nov; 25(11):e1640-e1649. PubMed ID: 32533785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.